Mara Aspinall, Chief Executive Officer at On-Q-ity, to Participate in Plenary Session at Partnering for Cures Meeting in New York
Waltham, MA - November 30, 2009 -- On-Q-ity, a next-generation oncology diagnostics company developing products to improve cancer therapy effectiveness, announced today that Mara Aspinall, On-Q-ity President and Chief Executive Officer, will take part in one of the plenary sessions at the Partnering for a Cure meeting to be held December 1-3 at the Millennium Broadway Hotel in New York City. The meeting, sponsored by the FasterCures organization, brings together innovators from philanthropy, medical research foundations, and the biotechnology and pharmaceutical industries with the goal of forging collaborations necessary to develop new medical solutions.
The plenary session, called "Breakthrough Science" will take place on December 3, 2009 at 8am ET in the Hudson Theater. The panel will discuss the most exciting new developments in medical science and the resources needed to support breakthrough science.
About FasterCures
FasterCures is the Washington, D.C.-based center of the Milken Institute. The Center is is committed to breaking down the barriers that exist across the research continuum - from basic research to drug development - to clear the path to faster medical progress.
About On-Q-ity
On-Q-ity is a next-generation diagnostics company dedicated to transforming cancer treatment through non-invasive diagnostic monitoring. The company is developing innovative diagnostics to identify the unique characteristics of an individual's cancer, predicting the response to therapy, and monitoring the efficacy of treatment. On-Q-ity was formed through the merger of Cellective DX, a developer of microfluidics devices to capture and analyze circulating tumor cells from the blood of cancer patients, with The DNA Repair Company, a molecular diagnostics company developing biomarker panels to predict response to cancer therapy based on DNA repair pathways in tumors.
The company's CTC and biomarker technologies originated from groundbreaking research at Massachusetts General Hospital and the Dana Farber Cancer Institute and MIT, respectively. Headquartered in Waltham, MA, On-Q-ity is funded by Bessemer Venture Partners, MDV-Mohr Davidow Ventures , Physic Ventures and Northgate Capital. For more information: www.On-Q-ity.com.
###
Media contact:
Stephanie Ashe; stephanie@continuumhealthcare.com; 650-728-7087
SOURCE On-Q-ity Inc.